Home › Companies › Aclaris Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Aclaris Therapeutics, Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2025-2026
Explore Aclaris Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Aclaris Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Anand Mehra, M.D. | 83,063,569 | -- | -- | 10,075,624 | 19,360,478 | Majority: yes |
| Elect Director: Maxine Gowen, Ph.D. | 84,209,108 | -- | -- | 8,930,085 | 19,360,478 | Majority: yes |
| Proposal 2: The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: | 83,370,124 | 9,734,691 | 34,378 | -- | 19,360,478 | Majority: yes |
| Proposal 3: The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast | 112,322,811 | 159,714 | 17,146 | -- | -- | Majority: yes |
Source: Aclaris Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.
Each item below shows how the 140 asset managers that disclosed a Aclaris Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Aclaris Therapeutics, Inc.’s own tally for this item (“Proposal 2: The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows:”): 83,370,124 for, 9,734,691 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 139,663,680 outstanding shares: 60% for, 7% against (67% of the company cast a for/against vote).
The 139 asset managers below cast 87% of the shares they voted on this item FOR (69,030,898 for, 9,931,022 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 9,345,000 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 8,316,239 | 0 | 0 | 0 | For |
| BlackRock | 6,946,406 | 56,214 | 0 | 0 | For |
| Vivo Capital, LLC | 6,666,666 | 0 | 0 | 0 | For |
| Vanguard | 6,624,202 | 7,792 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 4,925,374 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 4,472,650 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 4,041,736 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 3,871,000 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 2,426,094 | 0 | 0 | 0 | For |
| Fidelity | 2,080,153 | 322,240 | 0 | 0 | For |
| State Street | 1,812,872 | 25,061 | 0 | 0 | For |
| Kalehua Capital Management LLC | 1,832,365 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,271,329 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 1,035,652 | 0 | 0 | Against |
| Aldebaran Capital, LLC | 947,551 | 0 | 0 | 0 | For |
| Citadel | 800,367 | 0 | 0 | 0 | For |
| Northern Trust | 684,671 | 30,689 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 626,985 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 587,399 | 0 | 0 | 0 | For |
| Charles Schwab | 521,953 | 0 | 0 | 0 | For |
| Renaissance | 0 | 439,517 | 0 | 0 | Against |
| Aisling Capital Management LP | 434,455 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 418,525 | 0 | 0 | Against |
| Russell Investments | 418,061 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.
Combines 5 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Aclaris Therapeutics, Inc.’s own tally for this item (“Elect Director: Anand Mehra, M.D.”): 83,063,569 for, 10,075,624 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 139,663,680 outstanding shares: 59% for, 7% withheld (67% of the company cast a for/withheld vote).
The 47 asset managers below cast 100% of the shares they voted on this item FOR (13,870,850 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,922,577 | 0 | 7,642 | 0 | For |
| BlackRock | 4,271,236 | 0 | 0 | 0 | For |
| Fidelity | 2,080,153 | 0 | 144,393 | 0 | For |
| JPMorgan | 280,173 | 0 | 0 | 0 | For |
| Charles Schwab | 260,963 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 223,739 | 0 | Abstain |
| Equitable | 151,244 | 0 | 7,600 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 157,263 | 0 | 0 | 0 | For |
| Russell Investments | 140,937 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 140,259 | 0 | Abstain |
| Goldman Sachs | 119,875 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 118,702 | 0 | Abstain |
| Brighthouse | 75,268 | 0 | 38,982 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 102,584 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 98,175 | 0 | Abstain |
| TIAA | 0 | 0 | 90,480 | 0 | Abstain |
| Invesco | 80,559 | 0 | 0 | 0 | For |
| Lincoln Financial | 67,000 | 0 | 0 | 0 | For |
| Pacific Life | 35,716 | 0 | 19,779 | 0 | For |
| Global X | 43,454 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 42,353 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 42,210 | 0 | Abstain |
| AQR | 0 | 0 | 35,656 | 0 | Abstain |
| State Street | 33,633 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 28,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Combines 5 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Aclaris Therapeutics, Inc.’s own tally for this item (“Elect Director: Maxine Gowen, Ph.D.”): 84,209,108 for, 8,930,085 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 139,663,680 outstanding shares: 60% for, 6% withheld (67% of the company cast a for/withheld vote).
The 47 asset managers below cast 100% of the shares they voted on this item FOR (13,931,312 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,922,578 | 0 | 7,641 | 0 | For |
| BlackRock | 4,271,236 | 0 | 0 | 0 | For |
| Fidelity | 2,080,153 | 0 | 144,393 | 0 | For |
| JPMorgan | 280,173 | 0 | 0 | 0 | For |
| Charles Schwab | 260,963 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 223,739 | 0 | Abstain |
| Equitable | 158,844 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 157,263 | 0 | 0 | 0 | For |
| Russell Investments | 140,937 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 140,259 | 0 | Abstain |
| Goldman Sachs | 119,875 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 118,702 | 0 | Abstain |
| Brighthouse | 75,268 | 0 | 38,982 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 102,584 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 98,175 | 0 | Abstain |
| TIAA | 0 | 0 | 90,480 | 0 | Abstain |
| Invesco | 80,559 | 0 | 0 | 0 | For |
| Lincoln Financial | 67,000 | 0 | 0 | 0 | For |
| Pacific Life | 35,716 | 0 | 19,779 | 0 | For |
| Global X | 43,454 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 42,353 | 0 | 0 | 0 | For |
| Northern Trust | 42,210 | 0 | 0 | 0 | For |
| AQR | 0 | 0 | 35,656 | 0 | Abstain |
| State Street | 33,633 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 28,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Aclaris Therapeutics, Inc.’s own tally for this item (“Proposal 3: The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending”): 112,322,811 for, 159,714 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 139,663,680 outstanding shares: 80% for, 0.2% against (81% of the company cast a for/against vote).
The 47 asset managers below cast 100% of the shares they voted on this item FOR (15,057,933 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,930,219 | 0 | 0 | 0 | For |
| BlackRock | 4,271,236 | 0 | 0 | 0 | For |
| Fidelity | 2,224,546 | 0 | 0 | 0 | For |
| JPMorgan | 280,173 | 0 | 0 | 0 | For |
| Charles Schwab | 260,963 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 223,739 | 0 | 0 | 0 | For |
| Equitable | 158,844 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 157,263 | 0 | 0 | 0 | For |
| Russell Investments | 140,937 | 0 | 0 | 0 | For |
| Dimensional | 140,259 | 0 | 0 | 0 | For |
| Goldman Sachs | 119,875 | 0 | 0 | 0 | For |
| American Century | 118,702 | 0 | 0 | 0 | For |
| Brighthouse | 104,911 | 0 | 9,339 | 0 | For |
| AIG/SunAmerica | 102,584 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 98,175 | 0 | 0 | 0 | For |
| TIAA | 90,480 | 0 | 0 | 0 | For |
| Invesco | 80,559 | 0 | 0 | 0 | For |
| Lincoln Financial | 67,000 | 0 | 0 | 0 | For |
| Pacific Life | 55,495 | 0 | 0 | 0 | For |
| Global X | 43,454 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 42,353 | 0 | 0 | 0 | For |
| Northern Trust | 42,210 | 0 | 0 | 0 | For |
| AQR | 35,656 | 0 | 0 | 0 | For |
| State Street | 33,633 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 28,431 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Ranked by the number of Aclaris Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 139,663,680 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Deep Track Capital, LP | 6.69% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 5.95% |
| 3 | BlackRock | 5.01% |
| 4 | Vivo Capital, LLC | 4.77% |
| 5 | Vanguard | 4.75% |
| 6 | Frazier Life Sciences Management, L.P. | 3.53% |
| 7 | Rock Springs Capital Management LP | 3.20% |
| 8 | Decheng Capital LLC | 2.89% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.77% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.74% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BML Investment Partners, L.P. | 9.99% | 13G |
| Biosion, Inc. | 8.08% | 13G |
| Frazier Life Sciences Public Fund, L.P. | 5.64% | 13G |
| BlackRock | 5.30% | 13F |
| Vanguard Group | 4.66% | 13F |
| Vivo Opportunity Fund Holdings, L.P. | 4.27% | 13G |
| Morgan Stanley | 2.45% | 13F |
| Citadel Advisors | 2.02% | 13F |
| Geode Capital | 1.74% | 13F |
| State Street | 1.44% | 13F |
Percentages above are of 139,663,680 shares outstanding, as reported by Aclaris Therapeutics, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Aclaris Therapeutics, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Aclaris Therapeutics, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 140 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 624 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — FOR was 90% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Aclaris Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-04.
Aclaris Therapeutics, Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).